Table 3.
Results of meta-analysis for rs11549465 polymorphism and cancer risk
| Study Groups | NO.of studies | Case (TT/TC/CC) | Control (TT/TC/CC) | TT vs. CC | TC vs. CC | TT/TC vs. CC | TT vs. TC/CC | T vs. C | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| OR (95% CI) | Pa; Pb; I2 (%) | OR (95% CI) | Pa; Pb; I2 (%) | OR (95% CI) | Pa; Pb; I2 (%) | OR (95% CI) | Pa; Pb; I2 (%) | OR (95% CI) | Pa; Pb; I2 (%) | ||||
| All population | 28 | 7807 (120/1131/6556) | 8633 (55/1100/7478) | 2.15 (1.19-3.88) | 0.011; 0.010; 52.0% | 1.15 (0.96-1.36) | 0.127; 0.000; 63.8% | 1.19 (0.99-1.42) | 0.071; 0.000; 69.1% | 2.21 (1.60-3.05) | 0.010; 0.028; 45.5% | 1.20 (1.01-1.44) | 0.043; 0.000; 71.8% |
| Ethnicity | |||||||||||||
| Asian | 19 | 5281 (68/619/4594) | 5851 (18/571/5262) | 4.17 (2.48-7.01) | 0.000; 0.913; 0.0% | 1.19 (0.97-1.47) | 0.097; 0.003; 53.7% | 1.24 (0.99-1.55) | 0.063; 0.000; 60.7% | 3.70 (2.21-6.19) | 0.000; 0.936; 0.0% | 1.26 (1.01-1.57) | 0.041; 0.000; 63.2% |
| Caucasian | 9 | 2526 (52/512/1962) | 2782 (37/529/2216) | 1.34 (0.55-3.31) | 0.521; 0.012; 63.5% | 1.09 (0.79-1.50) | 0.613; 0.000; 76.3% | 1.12 (0.80-1.56) | 0.503; 0.000; 78.9% | 1.36 (0.57-3.21) | 0.489; 0.019; 60.4% | 1.13 (0.83-1.54) | 0.432; 0.000; 80.6% |
| Source of control | |||||||||||||
| Population | 11 | 4390 (44/596/3750) | 4883 (32/616/4235) | 1.39 (0.88-2.20) | 0.158; 0.067; 49.0% | 1.12 (0.84-1.50) | 0.430; 0.000; 73.4% | 1.14 (0.86-1.52) | 0.360; 0.000; 74.0% | 1.40 (0.89-2.22) | 0.148; 0.073; 47.9% | 1.15 (0.88-1.49) | 0.302; 0.000; 73.3% |
| Hospital | 17 | 3417 (76/535/2806) | 3750 (23/484/3243) | 3.75 (2.34-6.01) | 0.000; 0.326; 13.3% | 1.17 (0.94-1.46) | 0.164; 0.005; 53.3% | 1.21 (0.95-1.55) | 0.121; 0.000; 63.1% | 3.36 (2.10-5.37) | 0.000; 0.455; 0.0% | 1.23 (0.97-1.57) | 0.090; 0.000; 68.0% |
| Detection method | |||||||||||||
| PCR-Sequencing | 7 | 991 (1/134/856) | 977 (0/93/884) | 3.44 (0.14-85.66) | 0.451; -; - | 1.51 (0.78-2.94) | 0.000; 0.001; 75.0% | 1.54 (0.80-2.97) | 0.198; 0.001; 74.5% | 3.44 (0.14-85.40) | 0.452; -; - | 1.53 (0.84-2.79) | 0.000; 0.002; 71.3% |
| PCR-RFLP | 15 | 3584 (106/719/2759) | 4315 (47/698/3570) | 2.31 (1.12-4.73) | 0.000; 0.005; 61.6% | 1.15 (0.95-1.40) | 0.012; 0.010; 51.9% | 1.21 (0.97-1.52) | 0.098; 0.000; 66.0% | 2.21 (1.13-4.30) | 0.020; 0.016; 55.8% | 1.24 (0.98-1.56) | 0.000; 0.000; 73.2% |
| SNP-ITTM | 1 | 1332 (6/119/1207) | 1369 (1/123/1245) | 6.19 (0.74-51.48) | 0.092; -; - | 1.00 (0.77-1.30) | 0.988; -; - | 1.04 (0.80-1.35) | 0.769; -; - | 6.19 (0.74-51.49) | 0.092; -; - | 1.08 (0.84-1.39) | 0.543; -; - |
| Taqman | 3 | 1614 (7/133/1474) | 1652 (7/146/1499) | 0.97 (0.35-2.66) | 0.950; 0.397; 0.0% | 0.91 (0.71-1.17) | 0.477; 0.562; 0.0% | 0.92 (0.72-1.17) | 0.488; 0.486; 0.0% | 0.99 (0.36-2.71) | 0.842; 0.407; 0.0% | 0.92 (0.73-1.16) | 0.502; 0.415; 0.0% |
| PCR-LDR | 1 | 87 (0/4/83) | 106 (0/13/93) | - | - | 0.34 (0.11-1.10) | 0.072; -; - | 0.34 (0.11-1.10) | 0.072; -; - | - | - | 0.36 (0.12-1.13) | 0.079; -; - |
| SNaPShot | 1 | 199 (0/22/177) | 214 (0/27/187) | - | - | 0.86 (0.47-1.57) | 0.624; -; - | 0.86 (0.47-1.57) | 0.624; -; - | - | - | 0.87 (0.49-1.55) | 0.635; -; - |
| Cancer type | |||||||||||||
| HNSCC | 1 | 55 (0/10/45) | 110 (0/12/98) | - | - | 1.81 (0.73-4.51) | 0.199; -; - | 1.81 (0.73-4.51) | 0.199; -; - | - | - | 1.73 (0.72-4.15) | 0.217; -; - |
| Prostate | 4 | 2200 (32/386/1782) | 2438 (21/371/2046) | 2.02 (0.60-6.83) | 0.117; 0.090; 58.5% | 1.42 (0.84-2.40) | 0.062; 0.000; 87.7% | 1.46 (0.89-2.40) | 0.031; 0.000; 86.9% | 2.03 (0.58-7.16) | 0.124; 0.077; 60.9% | 1.43 (0.93-2.21) | 0.017; 0.000; 85.0% |
| Prostate in Asian | 1 | 662 (2/48/612) | 716 (0/57/659) | 5.38 (0.26-112.36) | 0.278; -; - | 0.91 (0.61-1.35) | 0.631; -; - | 0.94 (0.64-1.40) | 0.777; -; - | 5.42 (0.26-113.18) | 0.275; -; - | 0.99 (0.67-1.45) | 0.943; -; - |
| Prostate in Caucasian | 3 | 1538 (30/338/1170) | 1722 (21/313/1387) | 1.78 (0.43-7.40) | 0.427; 0.045; 75.2% | 1.71 (0.83-3.51) | 0.144; 0.000; 91.2% | 1.75 (0.89-3.47) | 0.107; 0.000; 90.7% | 1.78 (0.41-7.74) | 0.443; 0.038; 76.8% | 1.68 (0.94-3.02) | 0.081; 0.000; 89.5% |
| Breast | 5 | 2047 (25/263/1759) | 1972 (9/228/1735) | 2.16 (0.52-8.85) | 0.031; 0.084; 54.8% | 1.07 (0.88-1.29) | 0.516; 0.188; 35.0% | 1.07 (0.76-1.50) | 0.254; 0.061; 55.6% | 2.27 (1.06-4.87) | 0.035; 0.120; 48.6% | 1.09 (0.76-1.55) | 0.106; 0.022; 64.9% |
| Breast in Asian | 3 | 1832 (23/227/1582) | 1746 (4/182/1560) | 4.38 (1.58-12.12) | 0.004; 0.932; 0.0% | 1.14 (0.92-1.41) | 0.228; 0.211; 35.6% | 1.26 (0.89-1.79) | 0.198; 0.132; 50.7% | 4.16 (1.51-11.48) | 0.006; 0.911; 0.0% | 1.32 (0.93-1.86) | 0.115; 0.109; 54.9% |
| Breast in Caucasian | 2 | 215 (2/36/177) | 226 (5/46/175) | 0.34 (0.06-1.83) | 0.211; -; - | 0.75 (0.46-1.22) | 0.251; 0.388; 0.0% | 0.72 (0.44-1.16) | 0.178; 0.309; 3.2% | 0.39 (0.07-2.05) | 0.265; -; - | 0.71 (0.45-1.14) | 0.156; 0.286; 12.3% |
| Gynecologicc | 2 | 301 (14/62/225) | 321 (2/64/255) | 9.92 (2.15-45.66) | 0.003; -; - | 1.16 (0.77-1.75) | 0.488; 0.176; 45.4% | 1.31 (0.58-2.94) | 0.152; 0.048; 74.5% | 8.35 (1.85-37.75) | 0.006; -; - | 1.38 (0.58-3.29) | 0.020; 0.018; 82.2% |
| Gynecologic in Asian | 1 | 199 (0/22/177) | 214 (0/27/187) | - | - | 0.86 (0.47-1.57) | 0.624; -; - | 0.86 (0.47-1.57) | 0.624; -; - | - | - | 0.87 (0.49-1.55) | 0.635; -; - |
| Gynecologic in Caucasian | 1 | 102 (14/40/48) | 107 (2/37/68) | 9.92 (2.15-45.66) | 0.003; -; - | 1.53 (0.86-2.74) | 0.150; -; - | 1.96 (1.13-3.41) | 0.017; -; - | 8.35 (1.85-37.75) | 0.006; -; - | 2.11 (1.35-3.30) | 0.001; -; - |
| Colorectal | 3 | 348 (3/32/313) | 408 (2/66/340) | 1.91 (0.32-11.58) | 0.480; -; - | 0.34 (0.09-1.34) | 0.009; 0.030; 71.5% | 0.34 (0.08-1.41) | 0.016; 0.023; 73.4% | 1.97 (0.33-11.90) | 0.460; -; - | 0.38 (0.09-1.50) | 0.035; 0.021; 74.0% |
| Colorectal in Asian | 2 | 150 (0/4/146) | 150 (0/13/127) | - | - | 0.15 (0.02-1.01) | 0.051; 0.182; 43.8% | 0.15 (0.02-1.01) | 0.051; 0.182; 43.8% | - | - | 0.16 (0.02-1.15) | 0.069; 0.169; 47.1% |
| Colorectal in Caucasian | 1 | 198 (3/28/167) | 258 (2/43/213) | 1.91 (0.32-11.58) | 0.480; -; - | 0.83 (0.50-1.39) | 0.482; -; - | 0.88 (0.53-1.45) | 0.612; -; - | 1.97 (0.33-11.90) | 0.460; -; - | 0.94 (0.59-1.49) | 0.783; -; - |
| ESCC | 1 | 95 (0/11/84) | 104 (0/11/93) | - | - | 1.11 (0.46-2.69) | 0.822; -; - | 1.11 (0.46-2.69) | 0.822; -; - | - | - | 1.10 (0.47-2.60) | 0.827; -; - |
| Lung | 3 | 509 (38/134/337) | 566 (13/128/425) | 1.41 (0.07-30.44) | 0.000; 0.044; 75.3% | 1.13 (0.59-2.19) | 0.067; 0.018; 75.2% | 1.19 (0.51-2.76) | 0.003; 0.001; 85.6 | 1.38 (0.09-22.18) | 0.000; 0.065; 70.6% | 1.19 (0.50-2.86) | 0.000; 0.000; 88.9% |
| Lung in Asian | 2 | 368 (38/103/227) | 410 (11/85/314) | 4.88 (2.42-9.84) | 0.000; -; - | 1.56 (0.94-2.61) | 0.088; 0.230; 30.6% | 1.67 (0.79-3.54) | 0.183; 0.107; 61.5% | 4.04 (2.02-8.08) | 0.000; -; - | 1.68 (0.77-3.64) | 0.191; 0.084; 66.4% |
| Lung in Caucasian | 1 | 141 (0/31/110) | 156 (2/43/111) | 0.20 (0.01-4.25) | 0.303; -; - | 0.73 (0.43-1.24) | 0.241; -; - | 0.70 (0.41-1.18) | 0.177; -; - | 0.22 (0.01-4.59) | 0.327; -; - | 0.70 (0.43-1.13) | 0.144; -; - |
| Pancreatic | 1 | 263 (0/54/209) | 271 (0/29/242) | - | - | 2.16 (1.32-3.51) | 0.002; -; - | 2.16 (1.32-3.51) | 0.002; -; - | - | - | 2.02 (1.27-3.23) | 0.003; -; - |
| Glioma | 1 | 150 (2/27/121) | 150 (1/14/135) | 2.23 (0.20-24.92) | 0.514; -; - | 2.15 (1.08-4.29) | 0.030; -; - | 2.16 (1.10-4.21) | 0.025; -; - | 2.01 (0.18-22.45) | 0.569; -; - | 2.05 (1.09-3.83) | 0.025; -; - |
| Hepatocellular | 1 | 102 (0/8/94) | 347 (0/13/334) | - | - | 2.19 (0.88-5.43) | 0.092; -; - | 2.19 (0.88-5.43) | 0.092; -; - | - | - | 2.14 (0.87-5.23) | 0.096; -; - |
| OSCC | 2 | 479 (1/33/445) | 443 (0/20/423) | 6.14 (0.25-151.49) | 0.267; -; - | 1.28 (0.69-2.38) | 0.432; 0.501; 0.0% | 1.35 (0.73-2.49) | 0.334; 0.403; 0.0% | 6.01 (0.24-148.26) | 0.273; -; - | 1.41 (0.78-2.56) | 0.257; 0.323; 0.0% |
| Gastric | 1 | 87 (0/4/83) | 106 (0/13/93) | - | - | 0.34 (0.11-1.10) | 0.072; -; - | 0.34 (0.11-1.10) | 0.072; -; - | - | - | 0.36 (0.12-1.13) | 0.079; -; - |
| Bladder | 1 | 219 (0/22/197) | 461 (0/2/419) | - | - | 1.11 (0.65-1.92) | 0.697; -; - | 1.11 (0.65-1.92) | 0.697; -; - | - | - | 1.11 (0.65-1.88) | 0.704; -; - |
| RCC | 2 | 952 (5/85/862) | 936 (7/89/840) | 0.67 (0.21-2.15) | 0.498; 0.616; 0.0% | 0.92 (0.67-1.26) | 0.599; 0.283; 13.1% | 0.90 (0.67-1.22) | 0.509; 0.235; 29.2% | 0.69 (0.22-2.17) | 0.521; 0.640; 0.0% | 0.89 (0.67-1.19) | 0.432; 0.207; 37.1% |
| RCC in Asian | 1 | 620 (2/46/572) | 623 (2/43/578) | 1.01 (0.14-7.20) | 0.992; -; - | 1.08 (0.70-1.66) | 0.724; -; - | 1.08 (0.71-1.65) | 0.728; -; - | 1.00 (0.14-7.16) | 0.996; -; - | 1.07 (0.71-1.61) | 0.738; -; - |
| RCC in Caucasian | 1 | 332 (3/39/290) | 313 (5/46/262) | 0.54 (0.13-2.29) | 0.405; -; - | 0.77 (0.48-1.21) | 0.254; -; - | 0.74 (0.48-1.16) | 0.189; -; - | 0.56 (0.13-2.37) | 0.432; -; - | 0.74 (0.49-1.11) | 0.149; -; - |
a
P value for Z test.
b
P value for Q test for between-study heterogeneity.
c
Ovarian, cervical and endometrial cancer.
The numbers in parentheses represent 95% confidence interval [CI]. The bold numbers mean that the OR values for the contrast models are significant.